SCHEMBL2937879

SCHEMBL2937879

CN(C(=O)O)c1ccc2c(c1)OCO2

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.51
MAPK1 P28482 1/20 0.51
NPC1 O15118 8/20 0.51
RAB9A P51151 8/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
HPGD P15428 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.48
SRD5A2 P31213 1/20 0.46
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
CYP3A4 P08684 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C19 P33261 1/20 0.45
POLB P06746 1/20 0.45
GFER P55789 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24315702 0.86 KMT2A (0.49) ALDH1A1MAPK1NPC1RAB9ASMN1; SMN2
SCHEMBL3523972 0.85 NPC1 (0.47) ALDH1A1MAPK1NPC1RAB9ASMN1; SMN2
SCHEMBL9092221 0.85 NPC1 (0.47) ALDH1A1MAPK1NPC1RAB9ASMN1; SMN2
SCHEMBL14518799 0.83 NPC1 (0.46) ALDH1A1MAPK1NPC1RAB9ASMN1; SMN2
SCHEMBL30128152 0.83 HPGD (0.54) ALDH1A1MAPK1NPC1RAB9ASMN1; SMN2
SCHEMBL24667608 0.82 NPC1 (0.48) ALDH1A1NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL2091706 0.81 KMT2A (0.44) ALDH1A1MAPK1NPC1RAB9ASMN1; SMN2
SCHEMBL4883851 0.81 HPGD (0.47) ALDH1A1NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL19030882 0.79 NPC1 (0.48) ALDH1A1MAPK1NPC1RAB9ASMN1; SMN2
SCHEMBL14484813 0.79 NPC1 (0.44) ALDH1A1MAPK1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593079-B1 MENTHYL CARBAMATE COMPOUNDS AS SKIN AND/OR HAIR LIGHTENING ACTIVES SYMRISE AG (DE) 2016-11-16 EP disclosed
US-9060949-B2 Menthyl carbamate compounds as skin and/or hair lightening actives SYMRISE AG (DE) 2015-06-23 US disclosed
US-20130129646-A1 MENTHYL CARBAMATE COMPOUNDS AS SKIN AND/OR HAIR LIGHTENING ACTIVES SYMRISE AG (DE) 2013-05-23 US disclosed
WO-2013006408-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. (US) 2013-01-10 WO disclosed
EP-1836163-B1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN NOVARTIS AG (CH) 2010-09-22 EP disclosed
US-20100087427-A1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN BREITENSTEIN WERNER 2010-04-08 US disclosed
US-20080249075-A1 C11 Modified Retrosteroids as Progesterone Receptor Modulator Compounds SOLVAY PHARMACEUTICALS GMBH (DE) 2008-10-09 US disclosed
US-6967196-B1 Sulfonamide compounds and uses thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2005-11-22 US disclosed
US-4381936-A CARBAMATE STABILIZER WITH A THIOCARBAMATE STAUFFER CHEMICAL COMPANY (US) 1983-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087427-A1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN REN, ACE, PEPD ALDH1A1 494/4885MAPK1 2806/4885NPC1 4017/4885
US-20130129646-A1 MENTHYL CARBAMATE COMPOUNDS AS SKIN AND/OR HAIR LIGHTENING ACTIVES TYR, CRAT, SUCLG1 ALDH1A1 160/4885MAPK1 1159/4885NPC1 3818/4885
US-20080249075-A1 C11 Modified Retrosteroids as Progesterone Receptor Modulator Compounds HSD17B11, CYP19A1, ESRRA ALDH1A1 1234/4885MAPK1 1243/4885NPC1 1422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.